Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thiakis Ltd.

Division of Pfizer Inc.
www.thiakis.com

Latest From Thiakis Ltd.

Imperial Innovations raises £140M to back university spin-outs

Imperial Innovations, the publicly listed technology commercialisation and investment company, has raised £140 million in a warrants and rights issue to enable it to invest in companies based on intellectual property generated by Imperial College London, University College London and the universities of Oxford and Cambridge. Investors are able to buy the shares at 350p each, a 26.7% discount to the closing share price on 6 December.

Metabolic Disorders

UK Government Fund cornerstones £75M Advent Life Sciences fund

Advent Venture Partners has closed its first life sciences-focused venture capital fund at £75 million, with the UK Government's UK Future Technologies Fund investing £15 million in the round. Other limited partners in the fund wish to remain anonymous, Dr Shahzad Malik, General Partner, Advent Venture Partners, told Scrip. Dr Malik will co-manage the Advent Life Sciences fund with Advent General Partner Dr Raj Parekh.

PolyTherics makes appointment

PolyTherics, a UK-based biopharmaceutical company that applies precision chemistry to develop protein and peptide-based drugs, has named Dr John Burt chief business officer. He was previously CEO of Thiakis, a company which he co-founded with Professor Steve Bloom of Imperial College in 2004 and sold to Wyeth in 2008. Dr Burt has also previously worked at Imperial Innovations, GlaxoSmithKline and Vernalis.

Companies

Imperial Innovations "will deliver another Thiakis"

Further to the successful exit from the portfolio company Thiakis, the UK technology transfer firm Imperial Innovations believes it is well-placed to deliver more of the same.

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Steve Bloom, CSO
    Dunstan Cooke, IP & Lic. Mgr.
  • Contact Info
  • Thiakis Ltd.
    Phone: (44) (0) 20 7470 5621
    72 Hammersmith Rd.
    Crown House
    London, W14 8TH
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register